Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024 06:25 ET
|
Sandoz Group
All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024 09:00 ET
|
Sandoz Group
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m2...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
March 13, 2024 02:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up...
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024 13:24 ET
|
Sandoz Group
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®*...
Sandoz announces nominations to the Board of Directors and leadership change
March 05, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024 01:00 ET
|
Sandoz Group
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team...
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
February 29, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the classResolves...
Sandoz announces changes in the Board of Directors
February 01, 2024 01:15 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual...